Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79702.690.1727%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

TG Therapeutics Inc

TGTXNASDAQ
Trade with Public
Trade with Public
$55.98
-0.73-1.28%
At close: Sep 4, 5:00 PM EST
$56.00
0.0150.03%
After Hours: Sep 4, 7:04 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

TG Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for TG Therapeutics (TGTX).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

6Buy
1Hold
1Sell
Consensus RatingBuy# Analysts8Avg. Consensus PT$51Upside to Avg. PT-8.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026HC Wainwright & Co.Emily BodnarMaintainedBuy$78
Aug 7, 2026JP MorganBrian ChengPT RaiseOverweight$65→$72
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $78 price target.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72

JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $65 to $72.
Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $86

B. Riley Securities analyst William Woods maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $55 to $86.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77

HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $70 to $77.
Benzinga Newsdesk

PRO
B of A Securities Maintains Underperform on TG Therapeutics, Raises Price Target to $20

B of A Securities analyst Alec Stranahan maintains TG Therapeutics (NASDAQ:TGTX) with a Underperform and raises the price target from $17 to $20.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $70 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $70 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved